George Bakris: The Future of Finerenone as a Diabetes Treatment

November 24, 2020
Kenny Walter

Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

More studies are planned testing the impact of finerenone.

Initial studies testing finerenone as a treatment for type 2 diabetes so far have been positive.

The nonsteroidal, selective mineralocorticoid receptor antagonist has shown the ability to half the progression of chronic kidney disease (CKD), while reducing the risk of cardiovascular events in this patient population.

However, despite the initial success, there is still a lot to learn whether or not this family of medicine can move to the front of the line for diabetic patients with CKD.

In an interview with HCPLive®, George Bakris, MD, Department of Medicine, University of Chicago, called finerenone “new to the party” and said it is expected to be examined closer in the coming years.

Bakris said while the medication family has shown promise, it is unlikely they take the place of SGLT2 inhibitors, which have become increasingly popular for patients with type 2 diabetes and CKD to reduce the risk of negative cardiovascular outcomes.

The data was part of the ongoing Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial, which will assess the drug’s cardiorenal efficacy and safety in populations with type 2 diabetes and less advanced chronic kidney disease.